An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Icrucumab (Primary) ; Ramucirumab (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 25 Sep 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 16 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.